Europe Platelet Rich Plasma Market, Product Type (Pure-PRP, Leukocyte-Rich PRP, Pure Platelet Rich Fibrin, Others)

Europe Platelet Rich Plasma Market, Product Type (Pure-PRP, Leukocyte-Rich PRP, Pure Platelet Rich Fibrin, Others), By Origin (Autologous, Allogeneic/Homologues), By Application (Orthopaedics, Cosmetic Surgery and Dermatology, Neurosurgery, Cardiothoracic Surgery, General Surgery, Urology, Others), and By Country (U.K., Germany, France, Italy, Spain, Russia, Rest of Europe)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Platelet-rich plasma consists of two elements: plasma, or the liquid portion of blood, and platelets, a type of blood cell that plays an important role in healing throughout the body. Platelets are well-known for their clotting abilities, but they also contain growth factors that can trigger cell reproduction and stimulate tissue regeneration or healing in the treated area. Platelet-rich plasma is simply blood that contains more platelets than normal. Autologous platelet-rich plasma (PRP) is a blood plasma concentrate enriched with platelet count above the baseline of whole blood prepared from patient’s own blood. PRP is injected directly at the site of inflamed tissue releasing growth factor which stimulates and increases number of reparative cell in patient body. Platelet rich plasma protein consists of three proteins, which acts as cell adhesive molecules that are fibrin, fibronectin, and vitronectin. PRP is used for treatment of injured tendons, ligaments, muscles and joints Increasing prevalence of musculoskeletal injuries along with increasing prevalence of knee osteoarthritis is expected to boost growth of Europe platelet-rich plasma market over the forecast period.

Market Dynamics

Increasing adoption of organic growth strategies, such as product launch by key players in the market to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, on February 14 2023, Royal Biologics, an orthobiologics & life science company, announced the commercial launch of BIOINCYTE PRFM, a next-generation Platelet Rich Plasma (PRP) system, which converts traditional PRP to Platelet Rich Fibrin Matrix (PRFM) formulations and eliminates extensive contamination of red blood cells & white blood cells during the formulation of PRP.

Key features of the study:

This report provides in-depth analysis of the Europe platelet rich plasma, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the europe platelet rich plasma based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study are Vivostat A/S, Estar Medical, CosmoFrance Inc., Kelly Harris Aesthetics, Arthrex, Inc., Terumo Corporation, T-Biotechnology Ltd. St., EmCyte Corporation, Johnson & Johnson Private Limited, Zimmer Biomet, PRP Concepts, ADVACARE PHARMA, Isto Biologics, Arthrex, Inc., Stryker, GLOFINN, Medira Ltd, Regen Lab SA, Estar Technologies Ltd.

Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global platelet rich plasma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe platelet rich plasma

Detailed Segmentation:

Europe Platelet Rich Plasma Market, By PRP Type:

Pure-PRP

Leukocyte-Rich PRP

Pure Platelet Rich Fibrin

Others

Europe Platelet Rich Plasma Market, By Origin:

Autologous

Allogeneic/Homologues

Europe Platelet Rich Plasma Market, By Application:

Orthopaedics

Cosmetic Surgery and Dermatology

Neurosurgery

Cardiothoracic Surgery

General Surgery

Urology

Others

Europe Infection Surveillance Market, By Country:

U.K.

Germany

France

Italy

Spain

Russia

Rest of Middle East

Company Profiles

Vivostat A/S*

Company Highlights

Products Portfolio

Key Highlights

Financial Performance

Strategies

Estar Medical

CosmoFrance Inc.

Kelly Harris Aesthetics

Arthrex, Inc.

Terumo Corporation

T-Biotechnology Ltd. St.

EmCyte Corporation

Johnson & Johnson Private Limited

Zimmer Biomet

PRP Concepts

ADVACARE PHARMA

Isto Biologics

Arthrex, Inc.

Stryker

GLOFINN

Medira Ltd

Regen Lab SA

Estar Technologies Ltd.

“*” marked represents similar segmentation in other categories in the respective section.